Relative cost-effectiveness of a skin protectant in managing venous leg ulcers in the UK
Relative cost-effectiveness of a skin protectant in managing venous leg ulcers in the UK
复制标题
DOI：
10.12968/jowc.2012.21.8.389
复制
发表时间：
2012-08-01
影响因子：
1.9
通讯作者：
Vowden, P.
中科院分区：
文献类型：
--
作者：
Guest, J. F.;Taylor, R. R.;Vowden, P.
目的：评估在英国治疗腿部静脉溃疡 (VLU) 时使用皮肤保护剂（Cavilon 无刺屏障膜 [NSBF] 或 Cavilon 耐用屏障霜 [DBC]；3M）与不使用皮肤保护剂的临床和成本效益。方法：构建了一个决策模型，描述了一组使用和不使用 Cavilon 的患者的患者路径和相关管理 配方，加上敷料和压迫。该模型基于健康改善网络 (THIN) 数据库中一组匹配患者的病例记录，这些患者在 2008 年 1 月 1 日至 2009 年 12 月 31 日之间首次被诊断患有 VLU。该模型估计了 6 个月内患者管理的成本和结果，以及使用 Cavilon 配方相对于不使用皮肤保护剂的成本效益。结果：患者的平均年龄为 80.2 岁，其中 61% 为女性。 65% (n=166) 的 Cavilon 患者接受了 NSBF，35% 接受了 DBC。 6% 至 9% 的 VLU 在 6 个月时痊愈，53-66% 被感染。愈合受到患者年龄的影响（OR：每增加一年 0.944），但不受性别、渗出液水平或伤口大小的影响。 NSBF 组患者的伤口尺寸比其他两组患者明显减少（p
Objective: To estimate the clinical and cost-effectiveness of using a skin protectant (Cavilon No Sting Barrier Film [NSBF] or Cavilon Durable Barrier Cream [DBC]; 3M) compared with not using a skin protectant in the management of venous leg ulcers (VLUs), in the UK.Method: A decision model was constructed depicting the patient pathways and associated management of a cohort of patients with and without a Cavilon formulation, plus dressings and compression. The model was based on the case records of a cohort of matched patients from The Health Improvement Network (THIN) database, who were first diagnosed with a VLU between 1 Jan 2008 and 31 Dec 2009. The model estimated the costs and outcomes of patient management over 6 months and the cost-effectiveness of using a Cavilon formulation relative to not using a skin protectant.Results: Patients' mean age was 80.2 years and 61% were female. Sixty-five per cent (n=166) of Cavilon patients received NSBF, and 35% received DBC. Between 6% and 9% of VLUs were healed at 6 months and 53-66% became infected. Healing was affected by a patient's age (OR: 0.944 for each additional year), but not by gender, level of exudate or wound size. There was a significantly greater reduction in wound size among patients in the NSBF group than in the other two groups (p